Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU Medicines Agency Says Benefits of AstraZeneca Vaccine Still Outweigh Risks

04/07/2021 | 10:31am EDT

By Dan Michaels

BRUSSELS--The European Union's health agency said it had found possible links between AstraZeneca PLC's Covid-19 vaccine and rare blood clots but said the shot's benefits continue to outweigh potential risks. The European Medicines Agency found no specific risk factors linking the vaccine to the clots.

Write to Dan Michaels at dan.michaels@wsj.com

(END) Dow Jones Newswires

04-07-21 1030ET

All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049